WO2009100243A3 - Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients - Google Patents
Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients Download PDFInfo
- Publication number
- WO2009100243A3 WO2009100243A3 PCT/US2009/033253 US2009033253W WO2009100243A3 WO 2009100243 A3 WO2009100243 A3 WO 2009100243A3 US 2009033253 W US2009033253 W US 2009033253W WO 2009100243 A3 WO2009100243 A3 WO 2009100243A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- elavl4
- parkinson
- alzheimer
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Methods of screening patients with Alzheimer's Disease or Parkinson's Disease for risk of late-onset depression, by assaying a biological sample for the presence of ELAVL4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US690308P | 2008-02-05 | 2008-02-05 | |
US61/006,903 | 2008-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009100243A2 WO2009100243A2 (en) | 2009-08-13 |
WO2009100243A3 true WO2009100243A3 (en) | 2009-11-05 |
Family
ID=40952685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/033253 WO2009100243A2 (en) | 2008-02-05 | 2009-02-05 | Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009100243A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060068428A1 (en) * | 2003-11-03 | 2006-03-30 | Duke University | Identification of genetic markers associated with parkinson disease |
WO2006105907A1 (en) * | 2005-04-06 | 2006-10-12 | Diamed-Eurogen N.V. | Neurodegenerative markers for psychiatric conditions |
US20060257903A1 (en) * | 2005-03-31 | 2006-11-16 | Huda Akil | Compositions and methods for diagnosing and treating neuropsychiatric disorders |
-
2009
- 2009-02-05 WO PCT/US2009/033253 patent/WO2009100243A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060068428A1 (en) * | 2003-11-03 | 2006-03-30 | Duke University | Identification of genetic markers associated with parkinson disease |
US20060257903A1 (en) * | 2005-03-31 | 2006-11-16 | Huda Akil | Compositions and methods for diagnosing and treating neuropsychiatric disorders |
WO2006105907A1 (en) * | 2005-04-06 | 2006-10-12 | Diamed-Eurogen N.V. | Neurodegenerative markers for psychiatric conditions |
Non-Patent Citations (2)
Title |
---|
HAUGARVOLL, K. ET AL.: "ELAVL4, PARK10, and the Celts", MOV. DISORD., vol. 22, no. 4, 15 March 2007 (2007-03-15), pages 585 - 587 * |
NOUREDDINE, M. A. ET AL.: "Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease", HUM. GENET., vol. 117, no. 1, June 2005 (2005-06-01), pages 27 - 33 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009100243A2 (en) | 2009-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007087139A3 (en) | MESENCHYMAL STEM CELLS EXPRESSING TNF-α RECEPTOR | |
WO2007039290A3 (en) | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders | |
EP2617837A3 (en) | Biomarkers for predicting anti-TNF responsiveness or non-responsiveness | |
WO2005099716A3 (en) | Method for analyzing the biological age of a subject | |
GB2434205B (en) | Module for preparing a biological sample, biochip-assembly and use of the module | |
EP2485047A3 (en) | Methods and marker combinations for screening for predisposition to lung cancer | |
WO2010132479A3 (en) | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | |
WO2010045490A3 (en) | Human biomarker hypermapping for depressive disorders | |
HK1155330A1 (en) | Oilseed protein concentrates and isolates, and processes for the production thereof | |
WO2007039319A8 (en) | Dna microarray for rapid identification of candida albicans in blood cultures | |
WO2009121032A3 (en) | Sample preparation devices and methods for processing analytes | |
IL185501A0 (en) | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof | |
EP3284469A3 (en) | Compositions and methods for detection of lysosomal storage disease | |
WO2010005982A3 (en) | Multiplexed biomarkers of insulin resistance | |
EP2346387B8 (en) | Blood analysis | |
EP2700723A3 (en) | Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene | |
WO2011087709A3 (en) | Eml4-alk translocations in lung cancer | |
WO2006113289A3 (en) | Saposin d and fam3c are biomarkers for alzheimer's disease | |
IL223077A0 (en) | Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics | |
WO2011143574A3 (en) | Plasma biomarkers for diagnosis of alzheimer's disease | |
WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
WO2008112898A3 (en) | Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes | |
AU2010202926B2 (en) | Markers and methods relating to the assessment of Alzheimer's disease | |
WO2011143575A3 (en) | smFRET WITH MEMBRANE PROTEINS | |
WO2009129472A3 (en) | Methods of labeling biological samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09708407 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09708407 Country of ref document: EP Kind code of ref document: A2 |